Literature DB >> 10618273

Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria.

L Kirkeby1, T T Rasmussen, J Reinholdt, M Kilian.   

Abstract

Certain bacteria, including overt pathogens as well as commensals, produce immunoglobulin A1 (IgA1) proteases. By cleaving IgA1, including secretory IgA1, in the hinge region, these enzymes may interfere with the barrier functions of mucosal IgA antibodies, as indicated by experiments in vitro. Previous studies have suggested that cleavage of IgA1 in nasal secretions may be associated with the development and perpetuation of atopic disease. To clarify the potential effect of IgA1 protease-producing bacteria in the nasal cavity, we have analyzed immunoglobulin isotypes in nasal secretions of 11 healthy humans, with a focus on IgA, and at the same time have characterized and quantified IgA1 protease-producing bacteria in the nasal flora of the subjects. Samples in the form of nasal wash were collected by using a washing liquid that contained lithium as an internal reference. Dilution factors and, subsequently, concentrations in undiluted secretions could thereby be calculated. IgA, mainly in the secretory form, was found by enzyme-linked immunosorbent assay to be the dominant isotype in all subjects, and the vast majority of IgA (median, 91%) was of the A1 subclass, corroborating results of previous analyses at the level of immunoglobulin-producing cells. Levels of serum-type immunoglobulins were low, except for four subjects in whom levels of IgG corresponded to 20 to 66% of total IgA. Cumulative levels of IgA, IgG, and IgM in undiluted secretions ranged from 260 to 2,494 (median, 777) microg ml(-1). IgA1 protease-producing bacteria (Haemophilus influenzae, Streptococcus pneumoniae, or Streptococcus mitis biovar 1) were isolated from the nasal cavities of seven subjects at 2.1 x 10(3) to 7.2 x 10(6) CFU per ml of undiluted secretion, corresponding to 0.2 to 99.6% of the flora. Nevertheless, alpha-chain fragments characteristic of IgA1 protease activity were not detected in secretions from any subject by immunoblotting. Neutralizing antibodies to IgA1 proteases of autologous isolates were detected in secretions from five of the seven subjects but not in those from two subjects harboring IgA1 protease-producing S. mitis biovar 1. alpha-chain fragments different from Fc(alpha) and Fd(alpha) were detected in some samples, possibly reflecting nonspecific proteolytic activity of microbial or host origin. These results add to previous evidence for a role of secretory immunity in the defense of the nasal mucosa but do not help identify conditions under which bacterial IgA1 proteases may interfere with this defense.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618273      PMCID: PMC95818          DOI: 10.1128/CDLI.7.1.31-39.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  49 in total

1.  Increased risistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component.

Authors:  E Lindh
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

2.  Determination of immunoglobulin A concentrations in human nasal secretions with a serum immunoglobulin A standard.

Authors:  S B Greenberg; R D Rossen; H R Six; B D Baxter; R B Couch
Journal:  J Clin Microbiol       Date:  1978-10       Impact factor: 5.948

3.  Diurnal variation of nasal protein concentration.

Authors:  N Mygind; J Thomsen
Journal:  Acta Otolaryngol       Date:  1976 Sep-Oct       Impact factor: 1.494

4.  Comparison of the effect of elastase on human secretory IgA and serum IgA.

Authors:  A Tax; L Korngold
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

5.  [Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions].

Authors:  H Sorensen; N Mygind; C B Pedersen; S Prytz
Journal:  Acta Otolaryngol       Date:  1976 Sep-Oct       Impact factor: 1.494

6.  Proteolysis of human IgG by human polymorphonuclear leucocyte elastase produces an Fc fragment with in vitro biological activity.

Authors:  H E Prince; J D Folds; J K Spitznagel
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Studies on gonococcus infection. XVII. IgA1-cleaving protease in vaginal washings from women with gonorrhea.

Authors:  M Blake; K K Holmes; J Swanson
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

Review 8.  Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence.

Authors:  M Kilian; J Reinholdt; H Lomholt; K Poulsen; E V Frandsen
Journal:  APMIS       Date:  1996-05       Impact factor: 3.205

9.  Concentration of immunoglobulins in nasal secretion from children with recurrent infections in the upper airways.

Authors:  N Mygind; J A Wihl
Journal:  Acta Otolaryngol       Date:  1976 Sep-Oct       Impact factor: 1.494

10.  Development of allergen-specific T-cell memory in atopic and normal children.

Authors:  S L Prescott; C Macaubas; T Smallacombe; B J Holt; P D Sly; P G Holt
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

View more
  18 in total

Review 1.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

3.  Collection of nasal secretions for immunological analysis.

Authors:  Jean-Baptiste Watelet; Philippe Gevaert; Gabriele Holtappels; Paul Van Cauwenberge; Claus Bachert
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-09       Impact factor: 2.503

4.  Teleost skin, an ancient mucosal surface that elicits gut-like immune responses.

Authors:  Zhen Xu; David Parra; Daniela Gómez; Irene Salinas; Yong-An Zhang; Louise von Gersdorff Jørgensen; Rasmus Demuth Heinecke; Kurt Buchmann; Scott LaPatra; J Oriol Sunyer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-24       Impact factor: 11.205

5.  Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.

Authors:  Gestur Vidarsson; Natasja Overbeeke; Annette M Stemerding; Germie van den Dobbelsteen; Peter van Ulsen; Peter van der Ley; Mogens Kilian; Jan G J van de Winkel
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

Review 7.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

8.  Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx.

Authors:  Tracey A Zola; Elena S Lysenko; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

9.  Novel Two-Component System of Streptococcus sanguinis Affecting Functions Associated with Viability in Saliva and Biofilm Formation.

Authors:  Tarsila M Camargo; Rafael N Stipp; Lívia A Alves; Erika N Harth-Chu; José F Höfling; Renata O Mattos-Graner
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

10.  FcγRIII stimulation breaks the tolerance of human nasal epithelial cells to bacteria through cross-talk with TLR4.

Authors:  K Golebski; W Hoepel; C M van Drunen; J den Dunnen; D van Egmond; E J de Groot; G D Amatngalim; J M Beekman; W J Fokkens
Journal:  Mucosal Immunol       Date:  2019-01-21       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.